Connect with us

Global Health

Fatty Liver Disease Drug Market Research Report 2019-2025 : Pfizer, Conatus Pharmaceuticals, Novartis

Published

on

Press Release

This report analyzes the Global Fatty Liver Disease Drug market size (production, value, capacity and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.

This study report categorizes the worldwide Fatty Liver Disease Drug breakdown data by leading manufacturers, key region, product type and application, also researches the market share, market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, distributors, sales channels and Porter’s Five Forces Analysis.

To Get Sample Copy of Report, Click Here: http://marketinsights.biz/16560/#Request-Sample

Global Fatty Liver Disease Drug market size expected to reach xx Million USD by 2025, from xx Million USD in 2017, at a CAGR of xx% during the forecast period (2018-2025). In this study report, 2017 has been considered as the base year, 2018 as the Estimated Year, (2013-2017) as the History Year and 2018 to 2025 as the forecast period to estimate the market size for Fatty Liver Disease Drug.

This analysis report mainly focuses on the top manufacturers Fatty Liver Disease Drug production, value, price, capacity, and market share of Fatty Liver Disease Drug in the global market. The following manufacturers are covered in this report:

Pfizer, Conatus Pharmaceuticals, Novartis, Intercept Pharmaceuticals, Allergan, Immuron, Takeda, Gilead Sciences, Genfit

For Any Customization, Do Inquiry Here Before Purchasing Report: http://marketinsights.biz/16560/#Buying-Inquiry

Fatty Liver Disease Drug Breakdown Data by Type

By Type 1 , Granulocyte Colony Stimulating Factor Drug , Opioid Antagonist Drug , Pentoxifylline Drug , Glucocorticoid Drug , By Type 2 , Alcoholic Fatty Liver , Non Alcoholic Fatty Liver

Fatty Liver Disease Drug Breakdown Data by Application

Hospital, Medical Center

Fatty Liver Disease Drug Production Breakdown Data by Region

United States
Europe
China
Japan
Other Regions

Fatty Liver Disease Drug Consumption Breakdown Data by Region

North America (United States, Canada, Mexico)
Asia-Pacific (India, China, Japan, South Korea, Australia, Malaysia, Indonesia, Philippines, Vietnam, and Thailand)
Central & South America (Argentina, Brazil, Chile, Rest of South America)
Europe (Italy, UK, France, Russia, Germany, and Rest of Europe)
Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of the Middle East & Africa)

The report offers the following study objectives:

To research and analyze the worldwide Fatty Liver Disease Drug production, value, capacity, consumption, market status and forecast.
To focuses mainly on the global major Fatty Liver Disease Drug manufacturers and study the production, value, capacity, market share and development plans in the next few years.
To describe, analyze and define the market competition landscape, SWOT analysis.
To characterize, describe and forecast the market by type, application and key region.
To study the worldwide and key regions market advantage and potential, challenge and opportunity, risks and restraints.
To recognize important trends and factors driving or inhibiting market development.
To inspect the opportunities in the market for stakeholders by recognizing the high growth segments.
To strategically investigate each sub-market regarding individual growth trend and their contribution to the market.
To break down competitive advancements such as agreements, new product launches, expansions, and acquisitions in the market.
To deliberately profile the key players and extensively examines their growth strategies.

Table of Contents :

Global Fatty Liver Disease Drug Sales Market Report 2018 Mainly Covers Following Chapters:

1. Fatty Liver Disease Drug Overview(Product Overview, Scope and Classification of Fatty Liver Disease Drug), Type and Application of Fatty Liver Disease Drug, Fatty Liver Disease Drug Market by Regions;
2. Global Fatty Liver Disease Drug Competition by Manufacturers, Type, and Application with (Sales and Market Share, Revenue and Share, Volume and Value) by Manufacturers, by Type, by Regions and by Application;
3. United States Fatty Liver Disease Drug (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);
4. China Fatty Liver Disease Drug (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);
5. Europe Fatty Liver Disease Drug (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);
6. Japan Fatty Liver Disease Drug (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);
7. Global Fatty Liver Disease Drug Manufacturers Analysis(Company Basic Information, Manufacturing Base and Competitors, Product Type, Application and Specification), Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2011-2018), Main Business/Business Overview;
8. Fatty Liver Disease Drug Manufacturing Cost Analysis, Key Raw Materials Analysis(Key Raw Materials, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials), Proportion of Manufacturing Cost Structure(Labour Cost, Raw Materials, Manufacturing Process Analysis of Fatty Liver Disease Drug);
9. Industrial Chain Analysis, Upstream Raw Materials Sourcing, Sourcing Strategy and Downstream Buyers;
10. Marketing Strategy Analysis, Distributors/Traders with Marketing Channel(Direct Marketing, Indirect Marketing, Marketing Channel Development Trend),  Market Positioning(Pricing Strategy, Brand Strategy, Target Client), Distributors/Traders List;
11. Market Effect Factors Analysis (Technology Progress/Risk, Substitutes Threat, Technology Progress in Related Industry), Consumer Needs/Customer Preference Change, Economic/Political Environmental Change;
12. Global Fatty Liver Disease Drug Market Sales, Revenue Forecast (2018-2021) by Regions, by Type, by Application;
13. Appendix, Disclosure Section, Research Methodology, Data Source, Disclaimer.

Read Full TOC of Report with Charts, Figures, Tables Here: http://marketinsights.biz/16560/#Table-Of-Content

Thanks for reading this report; With the given information, We can also provide customization for Global Fatty Liver Disease Drug Market according to the company’s specific needs.

Contact Us:

Joel John
Sales Manager
Tel: +1-386-310-3803
Website: www.marketresearchbuzz.com
Referral Site: http://marketinsights.biz

This post was originally published on Health News Office

Continue Reading

Diseases & Disorders

Multiple Myeloma Market Focus to Boost Revenue with Massive Growth in Coming Years

Published

on

Press Release

Multiple Myeloma Market report analyses the prospects in the market for several shareholders and aspirants by identifying the high-growth segments, main actions approved by them and Multiple Myeloma market recent progressions. The Multiple Myeloma market report is prepared after fundamental levels of research regarding the Multiple Myeloma Industry.

 

Multiple Myeloma Market by Therapeutics Type [Chemotherapy and Other Drugs (Traditional Chemotherapy, Immunomodulating Agents, Proteasome Inhibitors, Histone Deacetylase (HDAC) Inhibitors, Monoclonal Antibodies), Radiation, and Stem Cell Transplant & Supportive Treatments] – Global Opportunity Analysis and Industry Forecast, 2020-2027

 

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/3725

 

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Celegene Corporation, Amgen Inc., Innate Pharma SA, and Celldex Therapeutics, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • The Multiple Myeloma Market size has been analyzed across all regions.
  • Porter’s five force analysis helps to analyze the potential of buyers & suppliers and the competitive scenario of the industry for strategy building
  • The report outlines the current market trends and future scenario of the market size from 2019 to 2027 to understand the prevailing opportunities and potential investment pockets.
  • Major countries in the regions have been mapped according to their individual revenue contribution.
  • The key drivers, restraints, and market opportunities and their detailed impact analysis are elucidated in the study.
  • The market analysis covers in-depth information of major industry participants.

 

Multiple Myeloma Market Key Segment:

By Therapeutics Type

  • Chemotherapy and Other Drugs
    • Traditional Chemotherapy
    • Immunomodulating Agents
    • Proteasome Inhibitors
    • Histone Deacetylase (HDAC) Inhibitors
    • Monoclonal Antibodies
  • Radiation
  • Stem Cell Transplant & Supportive Treatments

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 

For Purchase Enquiry:  https://www.alliedmarketresearch.com/purchase-enquiry/3725

This post was originally published on Health News Office

Continue Reading

General Health

APAC Anti-Inflammatory Therapeutics Market Value to raise $24.5 Billion by 2020

Asia-Pacific Anti-Inflammatory Therapeutics Market by Indication [Arthritis, Respiratory Disease, Multiple Sclerosis, Psoriasis, and Inflammatory Bowel Disease (IBD)], by Drug Class [Nonsteroidal Anti-Inflammatory Diseases (NSAIDs), Corticosteroids, Biologics, and Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)]: Asia-Pacific Opportunity Analysis and Industry Forecast, 2015-2020

Published

on

Asia-Pacific Anti-Inflammatory Therapeutics Market
Asia-Pacific Anti-Inflammatory Therapeutics Market
Press Release

Asia-pacific Anti-Inflammatory Therapeutics Market Outlook 2015-2020:

The Asia-Pacific Anti-Inflammatory Therapeutics Market is expected to grow $24.5 Billion by 2020 at a CAGR of 8.6% during the period of 2015-2020. The arthritis segment would continue to lead the Asia Pacific anti-inflammatory therapeutics market through 2020. China anti-inflammatory therapeutics market is forecast to grow at the highest CAGR of 13.9% during the forecast period.

The key companies profiled in this Asia-pacific Anti-Inflammatory Therapeutics Market report are Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc. Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca PLC and Amgen, Inc.

Companies have been adopting strategies such as collaborations, indication expansions and product launches as their key strategies to overcome the patent expiry issues of existing drugs and to gain additional market share.

Download Sample Copy of this Report at: https://www.alliedmarketresearch.com/request-sample/1175

Key Findings of the Anti-inflammatory Therapeutics Asia-Pacific Market:

  • China is expected to take over Japan by 2018 in the Asia Pacific anti-inflammatory therapeutics market
  • India anti-inflammatory therapeutics market is projected to account for around 13% share in the Asia-Pacific market by 2020
  • China and India would govern around half of the Asia-Pacific NSAID market by 2020
  • Japan accounted for around 1/3rd share in the anti-inflammatory biologics market in 2014, highest among all
  • Arthritis indication was the major revenue-generating segment in the APAC anti-inflammatory indication market in 2014
  • Psoriasis indication is projected to grow at a CAGR of 10.7%, fastest among all indications

Inflammation is a nonspecific immune defense mechanism of the body triggered due to injuries, bacterial or viral infections or any damage to the internal or external organs. When this inflammation persists for longer duration it can lead to chronic diseases such as atherosclerosis and rheumatoid arthritis, to name few. Currently, reduction of inflammation particularly in chronic diseases is the widely accepted therapeutic approach adopted by physicians.

First time buyer? Check offers and discount on this report: https://www.alliedmarketresearch.com/purchase-enquiry/1175

Rising incidences of autoimmune and respiratory diseases, increasing R&D investments in China and India and large amount of biosimilar drugs in the development pipeline would drive the growth of the Asia-Pacific anti-inflammatory therapeutics market. Furthermore, factors such as existence of established markets for NSAIDs and corticosteroids, large adoption of OTC (over the counter) NSAIDs, such as ibuprofen and naproxen, in China and India and government initiatives in the Asia-Pacific region would further boost the market growth. However, the adverse effects associated with prolonged consumption of drugs such as NSAIDs and corticosteroids and issues of uncertain patent legislations, such as compulsory licensing in India, would limit the market growth. High price sensitivity in countries such as India and China would be the key challenge for drug innovators to launch their patented drugs in the market.

The anti-inflammatory biologics segment dominated the market in 2014 and is expected to display the highest growth rate over the forecast period. This is due to the unmatched benefits offered by biological drugs and rapid adoption in countries like Japan along with improving healthcare access and increasing healthcare expenditures. Popularity of corticosteroids has been decreasing due to the issues of withdrawal symptoms and toxicity.

Japan is the leading market for patented as well as biologic drugs. However, government in Japan is now focusing on establishment of effective generic drugs. On the other hand, China is projected to emerge as the new market leader in the Asia-Pacific anti-inflammatory therapeutics market by 2020 due to rapidly developing economy, growing healthcare expenditure and huge patient base. In India, the launch of biosimilars and constantly improving per capita healthcare spending would be the key factors facilitating the growth of anti-inflammatory therapeutics market.

Read Blog at: https://blog.alliedmarketresearch.com/approval-for-new-anti-inflammatory-therapeutics-to-drive-growth-in-asia-pacific-region-209

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This post was originally published on Health News Office

Continue Reading

General Health

Biosurgery Market Value to raise $12.7 Billion by 2022 | AMR News

Biosurgery Market by Product Type (Anti-adhesive & Hemostatic agents, Natural surgical & Synthetic surgical sealant, Cell-based matrices, Bone morphogenetic proteins, Demineralized bone matrix, Soft tissue management (Biologic mesh/patch, Allografts, Xenografts, Synthetic mesh/patch)) and Application (Cardiovascular, Neuro- and spine, Orthopedic, Reconstructive, Urology, and Gynecology Surgeries)

Published

on

Biosurgery Market
Biosurgery Market
Press Release

Biosurgery Market Outlook 2014-2022:

Global Biosurgery Market is expected to garner $12.7 billion by 2022, registering a CAGR of 8.1% during the period 2014 – 2022. Hemostatic and surgical sealing agents segment collectively held about half of the market share in 2015, which is expected to flourish over the forecast period. The neuro and spine surgery application segment is likely to lead the biosurgery market throughout the study period.

The key companies profiled in this Biosurgery Market report are Medtronic PLC, Baxter International Inc., C. R. Bard Inc., Johnson and Johnson, Stryker Corporation, Sanofi S.A., Atrium Medical Corporation (Maquet Getinge Group), Hemostasis LLC, CryoLife Inc., and Kuros Bioscience.

Download Sample Copy of this Report at: https://www.alliedmarketresearch.com/request-sample/1235

Key findings of Biosurgery Market:

  • Surgical sealants are projected to be the fastest growing segment in the biosurgery market with a CAGR of 10.7% from 2015 to 2022.
  • Hemostatic agents segment is expected to overtake the bone graft substitute segment, and reach $4.3 billion by 2022.
  • Neuro- and spine surgery application segment is projected to dominate this market throughout the forecast period.
  • Biologic biosurgical products segment would continue to lead the biosurgery market with about three fourth of the market share in 2015.
  • Asia-Pacific is projected to be the fastest growing biosurgery market with a CAGR of 10.7% from 2015 to 2022.

The biosurgery market is projected to grow at a substantial rate owing to rise in sport & spine-related injuries, per capita healthcare expenditure, rise in the number of surgeries due to increase in obese population along with lifestyle disorders and others. Also, availability of multi-functional products would provide a lucrative market opportunity; for instance, apart from fibrins use as surgical sealants, it is also used as hemostatic agents to prevent excessive blood loss during cardiothoracic and orthopedic surgeries. However, factors that would hamper the market growth are high cost associated with surgeries, stern regulatory environment for product approval, and growing popularity of minimally invasive surgeries.

First time buyer? Check offers and discount on this report: https://www.alliedmarketresearch.com/purchase-enquiry/1235

The bone graft substitutes segment contributed to one-third share in the overall biosurgery market in 2015. This segment covers products such as cell-based matrices, bone morphogenetic proteins, demineralized bone matrix, and synthetic graft extenders. However, surgical sealant agents segment is expected to grow at the highest growth rate during the forecast period because of the availability of multifunctional products. The neuro- and spine surgery application segment is projected to dominate the market due to high penetration of bone graft substitute products usage in the surgeries. Also, current biologics products are more popular compared to synthetic biosurgical products, and this trend is expected to continue during the analysis period.

Source Medium: https://www.prnewswire.com/news-releases/world-biosurgery-market-is-expected-to-reach-127-billion-by-2022-575382521.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This post was originally published on Health News Office

Continue Reading

Trending